The Natural History of Subclinical Hyperthyroidism in Graves' Disease: The Rule of Thirds
Abstract
Background: There is little information regarding the natural history of subclinical hyperthyroidism (SH) due to Graves' disease (GD).
Methods: A prospective analysis was conducted of patients with SH due to GD between 2007 and 2013 with at least 12 months of follow-up. SH was diagnosed if serum thyrotropin (TSH) was below the laboratory reference range (0.4–4.0 mIU/L) and when thyroid hormones were normal. GD was confirmed by either a raised TSH receptor antibody (TRAb) level or uniform uptake on Technetium scan.
Results: Forty-four patients (89% female, 16% current smokers, and 5% with active Graves' orbitopathy) were diagnosed with SH due to GD. Over the follow-up period (median 32 months), approximately one third (34%) of the cohort progressed to overt hyperthyroidism, one third (34%) normalized their thyroid function, slightly less than one third (30%) remained in the SH state, while one person became hypothyroid. Multivariate regression analysis showed that older age and positive antithyroid peroxidase (TPO) antibody status had a positive association with risk of progression to overt hyperthyroidism, with hazard ratios of 1.06 ([confidence interval (CI) 1.02–1.10], p < 0.01) per year and 10.15 ([CI 1.83–56.23], p < 0.01), respectively, independent of other risk factors including, smoking, TRAb levels at diagnosis, and sex.
Conclusions: A third each of patients with SH due to GD progress, normalize, or remain in the SH state. Older people and those with positive anti-TPO antibodies have a higher risk of progression of the disease. These novel data need to be verified and confirmed in larger cohorts and over longer periods of follow-up.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA, McDermott MT 2005 Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J Clin Endocrinol Metab 90:581–585; discussion 586–587.
2.
Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE 2002 Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87:489–499.
3.
Vadiveloo T, Donnan PT, Cochrane L, Leese GP 2011 The Thyroid Epidemiology, Audit, and Research Study (TEARS): the natural history of endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab 96:E1–8.
4.
Vadiveloo T, Donnan PT, Cochrane L, Leese GP 2011 The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab 96:1344–1351.
5.
Diez JJ, Iglesias P 2009 An analysis of the natural course of subclinical hyperthyroidism. Am J Med Sci 337:225–232.
6.
Das G, Ojewuyi TA, Baglioni P, Geen J, Premawardhana LD, Okosieme OE 2012 Serum thyrotrophin at baseline predicts the natural course of subclinical hyperthyroidism. Clin Endocrinol (Oxf) 77:146–151.
7.
Rosario PW 2010 Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4 mIU/l: a prospective study. Clin Endocrinol (Oxf) 72:685–688.
8.
Abdul Shakoor SA, Hawkins R, Kua SY, Ching ME, Dalan R 2014 Natural history and comorbidities of subjects with subclinical hyperthyroidism: analysis at a tertiary hospital setting. Ann Acad Med Singapore 43:506–510.
9.
Poola R, Mathiason MA, Caplan RH 2011 A retrospective study of the natural history of endogenous subclinical hyperthyroidism. WMJ 110:277–280.
10.
Woeber KA 2005 Observations concerning the natural history of subclinical hyperthyroidism. Thyroid 15:687–691.
11.
Schouten BJ, Brownlie BE, Frampton CM, Turner JG 2011 Subclinical thyrotoxicosis in an outpatient population—predictors of outcome. Clin Endocrinol (Oxf) 74:257–261.
12.
Barbesino G, Tomer Y 2013 Clinical review: Clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab 98:2247–2255.
13.
Bartalena L, Pinchera A, Marcocci C 2000 Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 21:168–199.
14.
Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, Iervasi G, Asvold BO, Sgarbi JA, Volzke H, Gencer B, Maciel RM, Molinaro S, Bremner A, Luben RN, Maisonneuve P, Cornuz J, Newman AB, Khaw KT, Westendorp RG, Franklyn JA, Vittinghoff E, Walsh JP, Rodondi N, Thyroid Studies C 2012 Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 172:799–809.
15.
Rosario PW 2008 The natural history of subclinical hyperthyroidism in patients below the age of 65 years. Clin Endocrinol (Oxf) 68:491–492.
16.
Takasu N, Matsushita M 2012 Changes of TSH-stimulation blocking antibody (TSBAb) and thyroid stimulating antibody (TSAb) over 10 years in 34 TSBAb-positive patients with hypothyroidism and in 98 TSAb-positive Graves' patients with hyperthyroidism: reevaluation of TSBAb and TSAb in TSH-receptor-antibody (TRAb)-positive patients. J Thyroid Res 2012:182176.
17.
Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, Grimley Evans J, Hasan DM, Rodgers H, Tunbridge F, Young ET 1995 The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 43:55–68.
18.
Strieder TG, Tijssen JG, Wenzel BE, Endert E, Wiersinga WM 2008 Prediction of progression to overt hypothyroidism or hyperthyroidism in female relatives of patients with autoimmune thyroid disease using the Thyroid Events Amsterdam (THEA) score. Arch Intern Med 168:1657–1663.
Information & Authors
Information
Published In
Copyright
Copyright 2016, Mary Ann Liebert, Inc.
History
Published online: 13 June 2016
Published in print: June 2016
Published ahead of print: 10 May 2016
Published ahead of production: 18 April 2016
Topics
Authors
Author Disclosure Statement
The authors have no conflicts of interest to declare.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.